GlassScriptPhysician profile
Musib S Gappy
NPI 1477544088
$11,732.14
in general payments reported to CMS, 2019-2025
61 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $1,381 · 2021: $2,417 · 2022: $1,454 · 2023: $986 · 2024: $1,292 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,514.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,223.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $1,015.95 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $874.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $763.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ironwood Pharmaceuticals, INC | $717.28 | 2021-2025 | Linzess |
| Glaxosmithkline, LLC. | $644.35 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.24 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Abbvie INC. | $517.40 | 2019-2025 | |
| Lilly USA, LLC | $421.57 | 2019-2025 | Jardiance, Emgality, Reyvow |
| Pfizer INC. | $398.07 | 2019-2025 | |
| Amarin Pharma, INC. | $374.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $365.40 | 2019-2024 | Xarelto |
| Madrigal Pharmaceuticals | $274.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $272.43 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $240.92 | 2025 | Pyrukynd |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Musib Gappy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.